Search
Coccidioides immitis spherule
go.drugbank.com/drugs/DB11294ApprovedCoccidioides immitis spherule is a skin test antigen indicated to detect delayed-type hypersensitivity to Coccidioides immitis in individuals with a history of pulmonary coccidioidomycosis.
Tafasitamab
go.drugbank.com/drugs/DB15044ApprovedInvestigational[L15292,A191829] The CD19 surface protein is highly expressed on the surface of B-cells, where it appears to play a role in enhancing B-cell receptor signaling. … Tafasatimab is designed to bind to and block the activity of the CD19 surface antigen, which ultimately results in the lysis of B-cells (both healthy and malignant).
Categories: Lymphoma, B-CellMoxetumomab pasudotox
go.drugbank.com/drugs/DB12688ApprovedInvestigationalThis antibody was used to generate a recombinant immunotoxin in which a stabilized Fv segment by a disulfide bond is fused to the _Pseudomonas_ exotoxin A (PE38) which does not have the cell-binding portion … [A38864] MxP appears as an improved form of BL22 by the mutation of the Fv region and the antibody phage-displayed. As well the residues SSY in the heavy chain are mutated to THW.
Asunaprevir
go.drugbank.com/drugs/DB11586ApprovedWithdrawnIt has been shown to have a very high efficacy in dual-combination regimens with daclatasvir in patients chronically infected with HCV genotype 1b. … The commercialization of asunaprevir was cancelled one year later on October 16, 2017.[L1113]
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesProducts: SUNVEPRA® 100MG CÁPSULAS BLANDASAtezolizumab
go.drugbank.com/drugs/DB11595ApprovedInvestigationalAtezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers. … [A18493,L7489] This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy.
Categories: PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors, PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitorsProducts: Tecentriq Sc, TECENTRIQ SCFludarabine
go.drugbank.com/drugs/DB01073ApprovedInvestigationalFludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.
Categories: Heterocyclic Compounds, 2-Ring, DNA (Cytosine-5-)-Methyltransferases, antagonists & inhibitorsSynonyms: 2-F-ARAA, 2-fluoro ARA-AErythrityl tetranitrate
go.drugbank.com/drugs/DB01613ApprovedWithdrawnA vasodilator with general properties similar to nitroglycerin. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1020)
Synonyms: Tetranitrato de eritritilo, (2R*,3S)-rel-1,2,3,4-butanetetroltetranitrateDostarlimab
go.drugbank.com/drugs/DB15627ApprovedInvestigationalDostarlimab is an IgG<sub>4</sub> humanized monoclonal antibody targeted against the human programmed death receptor-1 (PD-1). … [L33320] PD-1 receptors are found on T-cells and, when activated, serve to inhibit immune responses - some cancers leverage this system by overexpressing PD-1 ligands, thereby effectively inhibiting the
Synonyms: Immunoglobulin G4, anti-programmed cell death protein 1 (PDCD1) (humanized clone ABT1 gamma4-chain), disulfide with humanized clone ABT1 kappa-chain, dimerCategories: PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors, PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitorsValdecoxib
go.drugbank.com/drugs/DB00580ApprovedWithdrawnValdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about a possible increased risk of heart attack and stroke.
Categories: COX-2 Inhibitors, Cytochrome P-450 SubstratesProducts: PARALGEN ® 40, PARALGEN ® 20 TABLETASDamoctocog alfa pegol
go.drugbank.com/drugs/DB14700ApprovedInvestigational[A38907] Also known as, BAY94-9027, Damoctocog alfa pegol is a longer-acting Factor VIII therapy formulated with polyethylene glycol (PEG) to reduce the number of infusions necessary to prevent bleeds … In order to extend half-lives, techniques such as fusion to protein conjugates (Fc part of IgG1 or albumin), chemical modification (PEGylation), and protein sequence modification have been utilized.